Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest gastrointestinal stromal tumor Stories

2009-06-01 08:02:00

Company Expands Diagnostic Services with K9 Clone DOG-1 Immunohistochemical and H. pylori Monoclonal Antibody Tests LAKEWOOD, N.J., June 1 /PRNewswire/ -- PLUS Diagnostics, a leading U.S. anatomic pathology company offering a full range of multi-specialty services, announced today that it is the first national laboratory to offer a highly specialized test that definitively diagnoses the rare gastrointestinal stromal tumor ("GIST"). Known as the K9 clone DOG-1 immunohistochemical assay, the...

2009-05-19 06:00:00

Partner Keryx to present Phase 2 data on perifosine for multiple cancers QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108, in prostate cancer, will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be...

2009-05-18 07:29:00

Results Will be Reported from Phase 2 Studies Evaluating KRX-0401 in Advanced Renal Cell Carcinoma, Colorectal Cancer and Gastrointestinal Stromal Tumors (GIST) NEW YORK, May 18 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that four abstracts on KRX-0401 (Perifosine), the Company's Akt-inhibitor for cancer, were accepted for presentation during poster sessions taking place at the 45th Annual Meeting of the American Society of Clinical Oncology...

2009-05-15 09:34:27

Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.Lori Rink, PhD, a postdoctoral fellow in the laboratory of Andrew K. Godwin, PhD, at Fox Chase, presents their findings at the 2009 Annual Meeting of the American...

2009-05-08 00:00:00

FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) After Surgery Significantly Reduces Risk of Cancer Relapse(2) - If Untreated After Surgery, 50% of patients Will Experience Their Cancer Returning Within Two Years(3,4) Glivec(R) has been...

2009-03-18 17:37:00

- Estimated one-year, recurrence-free survival was 98% for Kit-positive GIST patients taking Gleevec vs. 83% for patients taking placebo(1) - Historically, one in two patients experienced recurrence of GIST(2) within a median of two years after surgery(3) - Gleevec is the only treatment in the US and Switzerland indicated to reduce risk of recurrence of GIST after surgery; regulatory review is underway in the EU(4) EAST HANOVER, N.J., March 18, 2009 /PRNewswire/ -- Data published today...

2009-01-15 06:34:50

Research published in Journal of the American College of Surgeons finds survival rate of nearly 80 percent New research published in the January issue of the Journal of the American College of Surgeons shows that laparoscopic removal of gastrointestinal stromal tumors (GISTs) is safe and effective, with a disease-free survival rate of nearly 80 percent after an average follow-up time of three and a-half years. GIST is a type of cancer arising from special cells in the wall of the...

2008-12-19 18:41:00

Use of Gleevec after surgery shows significant benefit for gastrointestinal stromal tumor (GIST) patients, dramatically reducing risk of relapse GIST, a life-threatening cancer, recurs in as many as one of two patients; recurrent tumors are often more aggressive than primary tumors For GIST patients who were assigned to Gleevec, more than nine out of 10 remained cancer-free based on a 14-month median follow up EAST HANOVER, N.J., Dec. 19 /PRNewswire/ -- Novartis announced today...

2008-10-27 12:00:30

Infinity Pharmaceuticals, a cancer drug discovery and development company, has initiated a Phase III registration trial of IPI-504, its lead inhibitor of heat shock protein 90, in patients with refractory gastrointestinal stromal tumors. The Ring trial is a randomized, double-blind, placebo-controlled study evaluating approximately 200 patients with refractory gastrointestinal stromal tumors (GIST) in over 20 countries and 50 sites worldwide. Patients whose tumors have grown despite...

2008-09-08 18:00:09

Pfizer announced today that important study results involving the company's leading anticancer agent, SUTENT(R) (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12--16 September 2008. Researchers will present results of several analyses evaluating the cost effectiveness of SUTENT(R) as first-line therapy in patients with metastatic renal cell carcinoma...